Results 11 to 20 of about 564,426 (377)

Non-Hodgkin lymphoma

BMJ, 2018
The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising from cells of the immune system and manifesting predominantly as lymphadenopathy or solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 different subtypes listed in the latest WHO classification of lymphoma (1).
Bowzyk Al-Naeeb, Anna, Ajithkumar, Thankamma, Behan, Sarah, Hodson, Daniel James   +3 more
openaire   +4 more sources

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints

Haematologica, 2016
Classical Hodgkin lymphoma is curable in the majority of cases with chemotherapy and/or radiation. However, 15–20% of patients ultimately relapse and succumb to their disease.
Santosha Vardhana, Anas Younes
doaj   +2 more sources

Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma

Haematologica, 2016
Classical Hodgkin lymphoma is one of the most common lymphomas and shares clinical and genetic features with primary mediastinal B-cell lymphoma. In this retrospective study, we analyzed the recurrent hotspot mutation of the exportin 1 (XPO1, p.E571K ...
Vincent Camus, Aspasia Stamatoullas, Sylvain Mareschal, Pierre-Julien Viailly, Nasrin Sarafan-Vasseur, Elodie Bohers, Sydney Dubois, Jean Michel Picquenot, Philippe Ruminy, Catherine Maingonnat, Philippe Bertrand, Marie Cornic, Valérie Tallon-Simon, Stéphanie Becker, Liana Veresezan, Thierry Frebourg, Pierre Vera, Christian Bastard, Hervé Tilly, Fabrice Jardin   +19 more
doaj   +2 more sources

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead [PDF]

Journal of Clinical Oncology, 2015
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in
Auperin, Anne, Brugi\ue8res, Laurence, Burkhardt, Birgit, Cairo, Mitchell S, Damm Welk, Christine, Gross, Thomas G, Horibe, Keizo, Klapper, Wolfram, Lamant, Laurence, Le Deley, Marie C\ue9cile, Macintyre, Elizabeth, Minard Colin, V\ue9ronique, Mussolin, Lara, Patte, Catherine, Perkins, Sherrie L, Pillon, Marta, Poirel, H\ue9l\ue8ne A, Raphael, Martine, Reiter, Alfred, Rosolen, Angelo, Sandlund, John T, Williams, Denise, Woessmann, Wilhelm, Zimmerman, Martin   +23 more
core   +2 more sources

Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis

Journal of Hematology & Oncology, 2022
Background Hodgkin lymphoma is a lymphatic malignancy commonly found in cervical lymph nodes. This study evaluated the worldwide incidence, mortality, associated risk factors, and temporal trends of Hodgkin lymphoma by sex, age, and country.
Junjie Huang, W. Pang, Veeleah Lok, Lin Zhang, D. Lucero-Prisno, Wanghong Xu, Zhi‐Jie Zheng, Edmar Elcarte, M. Withers, Martin C. S. Wong   +9 more
semanticscholar   +1 more source

Molecular biology of Hodgkin lymphoma

Leukemia, 2021
Classical Hodgkin lymphoma (cHL) is unique among lymphoid malignancies in several key biological features. (i) The Hodgkin and Reed-Sternberg (HRS) tumor cells are rare among an extensive and complex microenvironment.
M. Weniger, R. Küppers
semanticscholar   +1 more source

Epidemiology of Non-Hodgkin’s Lymphoma

Medical Science, 2021
Non-Hodgins’s lymphoma (NHL) is the most common hematological malignancy worldwide, accounting for nearly 3% of cancer diagnoses and deaths. NHL is the seventh most prevalent cancer and has the sixth highest mortality among cancers in the US.
K. Thandra, A. Barsouk, Kalyan Saginala, S. Padala, Alexander Barsouk, Prashanth Rawla   +5 more
semanticscholar   +1 more source

Immunohistochemical Expression of B Cell Transcription Factors in Hodgkin’s Lymphoma and Their Use in Differential Diagnosis

Journal of Contemporary Medicine, 2023
Aim: Classical Hodgkin lymphoma is common, it is one of the lymphomas whose differential diagnosis can be difficult. It is thought that Hodgkin cell may originate from the germinal center.
Yiğit Şenol, Filiz Yavaşoğlu, Çiğdem Özdemir   +2 more
doaj   +1 more source

Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2020
Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8480 new patients annually and representing approximately 10% of all lymphomas in the United States.
S. Ansell
semanticscholar   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +5 more sources